Drug Type Recombinant polypeptide, Biosimilar |
Synonyms Liraglutide Biosimilar (Glenmark Pharmaceuticals Ltd.), Lirafit |
Target |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date IN (03 Jan 2024), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | IN | 03 Jan 2024 |